Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOther Non Operating IncomeProfit After TaxRent ExpenseResearch & DevelopmentSelling, General & AdministrativeShare-based Compensation (IS)Share-based Compensation (IS)Shares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Alterity Therapeutics (ATHE) Shares Outstanding (Weighted Average) (2016 - 2025)

Alterity Therapeutics has reported Shares Outstanding (Weighted Average) over the past 5 years, most recently at $603.0 million for Q2 2019.

  • For Q2 2019, Shares Outstanding (Weighted Average) rose 49.19% year-over-year to $603.0 million; the TTM value through Jun 2019 reached $603.0 million, up 49.19%, while the annual FY2019 figure was $603.0 million, 49.19% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q2 2019 was $603.0 million at Alterity Therapeutics, up from $1.1 million in the prior quarter.
  • Over five years, Shares Outstanding (Weighted Average) peaked at $105707.5 billion in Q4 2015 and troughed at $522946.2 in Q4 2017.
  • A 5-year average of $11745.5 billion and a median of $112.1 million in 2015 define the central range for Shares Outstanding (Weighted Average).
  • Biggest five-year swings in Shares Outstanding (Weighted Average): plummeted 100.0% in 2016 and later surged 273.59% in 2018.
  • Year by year, Shares Outstanding (Weighted Average) stood at $105707.5 billion in 2015, then plummeted by 100.0% to $1.1 million in 2016, then tumbled by 51.92% to $522946.2 in 2017, then surged by 112.63% to $1.1 million in 2018, then surged by 54127.69% to $603.0 million in 2019.
  • Business Quant data shows Shares Outstanding (Weighted Average) for ATHE at $603.0 million in Q2 2019, $1.1 million in Q4 2018, and $404.2 million in Q2 2018.